HC Wainwright Issues Optimistic Estimate for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.59) per share for the quarter, up from their previous forecast of ($0.64). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($3.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($3.10) EPS.

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.

Olema Pharmaceuticals Stock Up 0.2 %

OLMA stock opened at $4.12 on Friday. The company’s 50-day simple moving average is $5.11 and its 200-day simple moving average is $8.40. Olema Pharmaceuticals has a 52-week low of $3.94 and a 52-week high of $16.62. The firm has a market cap of $236.07 million, a P/E ratio of -1.88 and a beta of 2.11.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.12.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new position in Olema Pharmaceuticals in the 4th quarter worth approximately $30,000. Hsbc Holdings PLC purchased a new position in Olema Pharmaceuticals in the 4th quarter worth approximately $58,000. Teacher Retirement System of Texas purchased a new position in Olema Pharmaceuticals in the 4th quarter worth approximately $60,000. Vontobel Holding Ltd. purchased a new position in Olema Pharmaceuticals in the 4th quarter worth approximately $62,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Olema Pharmaceuticals by 43.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock worth $62,000 after buying an additional 3,185 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were acquired at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the purchase, the insider now directly owns 7,800,000 shares of the company’s stock, valued at $44,928,000. This trade represents a 4.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 19.40% of the stock is currently owned by corporate insiders.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.